✦ LIBER ✦

Vitamin D Reduces Musculoskeletal Pain After Infusion of Zoledronic Acid for Postmenopausal Osteoporosis

✍ Scribed by Antonino Catalano; Nancy Morabito; Marco Atteritano; Giorgio Basile; Domenico Cucinotta; Antonino Lasco

Book ID: 113023169
Publisher: Springer
Year: 2012
Tongue: English
Weight: 184 KB
Volume: 90
Category: Article
ISSN: 1432-0827
DOI: 10.1007/s00223-012-9577-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Once-Yearly Zoledronic Acid for Treatmen

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

✍ Black, Dennis M.; Delmas, Pierre D.; Eastell, Richard; Reid, Ian R.; Boonen, Ste 📂 Article 📅 2007 🏛 Massachusetts Medical Society 🌐 English ⚖ 510 KB

Effects of intravenous zoledronic acid p

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

✍ Felicia Cosman; Erik Fink Eriksen; Chris Recknor; Paul D Miller; Núria Guañabens 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 204 KB

The high prevalence of vitamin D insuffi

The high prevalence of vitamin D insufficiency in postmenopausal women (PMW) with osteoporosis (OP) has not been significantly reduced after 12 months of treatment with Ca and vitamin D

✍ A.E. Georgiadis; F. Papadopoulou; L. Tzianoumis; E. Georgiou 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Bone material properties in actively bon

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci

Effects of Yearly Zoledronic Acid 5 mg o

Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis

✍ Pierre D Delmas; Francoise Munoz; Dennis M Black; Felicia Cosman; Steven Boonen; 📂 Article 📅 2009 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 653 KB

Efficacy and safety of a once-yearly i.v

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi